Encompass Health to Report Q1 2026 Results on April 30

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 07 2026

0mins

EHC+0.85%

Should l Buy EHC?

Source: Newsfilter

Earnings Release Schedule: Encompass Health will report its Q1 2026 results after market close on April 30, 2026, providing key financial metrics and operational performance insights that will help investors assess the company's future growth potential.
Investor Conference Call: The company will host an investor conference call at 10 a.m. ET on May 1, 2026, to discuss the earnings results, which is expected to attract significant attention from analysts and investors, thereby enhancing market transparency.
Global Business Overview: Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with 174 hospitals across 39 states and Puerto Rico, demonstrating its leadership position in the healthcare sector by providing high-quality rehabilitative care.
Industry Recognition: The company has been recognized by Newsweek and Statista as America's Most Awarded Leader in Inpatient Rehabilitation and ranks among Fortune's World's Most Admired Companies and Forbes' America's Best Companies, reflecting its strong reputation and competitive advantage in the industry.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy EHC?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on EHC

Wall Street analysts forecast EHC stock price to rise

5 Analyst Rating

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 105.490

Low

134.00

Averages

146.75

High

160.00

Current: 105.490

Low

134.00

Averages

146.75

High

160.00

Barclays

NULL -> Overweight

maintain

$150 -> $153

2026-02-06

Reason

Barclays

Price Target

$150 -> $153

AI Analysis

2026-02-06

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Encompass Health to $153 from $150 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 report.

Barclays

Andrew Mok

Overweight

maintain

$141 -> $150

2025-10-30

Reason

Barclays

Andrew Mok

Price Target

$141 -> $150

2025-10-30

maintain

Overweight

Reason

Barclays analyst Andrew Mok raised the firm's price target on Encompass Health to $150 from $141 and keeps an Overweight rating on the shares. The company reported a modest Q4 beat, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EHC

Unlock Now

About EHC

Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Marion Jones Returns to Boston Marathon After Rare Disease Recovery

49 minutes agoCNBC

Rare Disease Diagnosis: Marion Jones was ultimately diagnosed with Neuromyelitis Optica (NMO) after multiple medical consultations, a rare autoimmune disorder that affects the optic nerves and spinal cord, leading to partial paralysis and a significant decline in her quality of life.
Challenging Rehabilitation: At Encompass Rehabilitation Hospital, Jones underwent three hours of intensive therapy daily, and through her dedication, she progressed from being wheelchair-bound to using a walker, showcasing remarkable recovery progress.
Reviving Running Aspirations: During an outpatient therapy session, Jones was challenged to run on a treadmill, managing only 30 seconds initially, but this reignited her passion for running, allowing her to gradually increase her distance from one minute to a mile, rekindling her athletic dreams.
Victory at Boston Marathon: Jones is set to complete the Boston Marathon, earning the Abbott World Marathon Majors Six Star Finisher Medal, symbolizing her triumph over adversity, while also raising funds for the rare disease community, reflecting her resilience and commitment to advocacy.

Pomerantz LLP Investigates Encompass Health Securities Fraud Claims

5 days agoGlobenewswire

Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation, focusing on whether its executives engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
Safety Issues Exposed: An article by The New York Times reported that Encompass-operated for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly higher rates of preventable readmissions, potentially triggering regulatory scrutiny and legal liabilities.
Significant Stock Drop: Following the publication of the report, Encompass's stock price fell by $12.39 on July 15, 2025, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns over the company's operational safety.
Potential Legal Consequences: This investigation may lead to a class action lawsuit, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking damages for affected investors, further impacting the company's reputation and financial standing.

Pomerantz LLP Investigates Encompass Health Securities Fraud Claims

Apr 07 2026Globenewswire

Securities Fraud Investigation: Pomerantz LLP is investigating claims against Encompass Health Corporation and its executives for potential securities fraud or other unlawful business practices, which may lead to significant investor losses.
Safety Issues Exposed: An article published by The New York Times on July 15, 2025, alleged that for-profit hospitals operated by Encompass perform below average on key safety measures, with 34 facilities rated as having significantly higher rates of preventable readmissions, potentially undermining investor confidence.
Stock Price Plunge: Following the publication of the article, Encompass's stock price fell by $12.39, a decline of 10.35%, closing at $107.28 per share, reflecting market concerns regarding the safety of the company's operations.
Potential Legal Action: The investigation by Pomerantz LLP may lead to a class action lawsuit, with investors encouraged to contact the firm to explore joining the action, which could further impact Encompass's market performance.